LX2006 Receives Rare Pediatric Disease and Orphan Drug Designations for Friedreich’s Ataxia
source: pixabay.com

LX2006 Receives Rare Pediatric Disease and Orphan Drug Designations for Friedreich’s Ataxia

The FDA grants designations, such as the Rare Pediatric Disease and Orphan Drug designations, to aid in the drug development process. Recently, LEXEO Therapeutics has received these two designations for…

Continue Reading LX2006 Receives Rare Pediatric Disease and Orphan Drug Designations for Friedreich’s Ataxia
New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
mcmurryjulie / Pixabay

New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports

A recent announcement in Biospace by Capsida Biotherapeutics and CRISPR Therapeutics of their newly-formed partnership offers renewed hope for amyotrophic lateral sclerosis (ALS) and Friedreich’s Ataxia patients. The companies believe…

Continue Reading New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
LX1001 for APOE4-Associated Alzheimer’s Granted Fast Track Designation
Thor_Deichmann / Pixabay

LX1001 for APOE4-Associated Alzheimer’s Granted Fast Track Designation

  In a recent press release, biotechnology and gene therapy company LEXEO Therapeutics ("LEXEO") shared that its gene therapy LX1001 received Fast Track designation from the FDA. Overall, LX1001 is…

Continue Reading LX1001 for APOE4-Associated Alzheimer’s Granted Fast Track Designation